Regencell Bioscience Holdings Limited entered into a sales agreement with Univest Securities, LLC to sell up to $500 million of its ordinary shares through an at‑the‑market (ATM) program. The agreement, effective March 30, 2026, allows the company to issue shares on a continuous basis as market conditions permit, providing a flexible source of capital while limiting market impact.
The ATM program is backed by a shelf registration statement on Form F‑3 that became effective on the same day, and a prospectus supplement was filed to disclose the terms of the offering. Regencell intends to use the proceeds for working capital, capital expenditures, and general corporate purposes, a strategy that aligns with its need to fund ongoing research and development of Traditional Chinese Medicine‑based therapies for neurocognitive disorders such as ADHD and ASD.
Regencell’s financial profile underscores the urgency of the capital raise. The company has reported zero revenue growth over the past three years and continues to post losses, with an earnings‑per‑share of –$0.01. In June 2024, cash reserves stood at $8.0 million and a trailing‑twelve‑month burn of $4.0 million, implying a runway of roughly two years. The ATM offering therefore represents a critical buffer against liquidity constraints as the company pursues clinical milestones.
Market sentiment around Regencell has been negative, with a consensus “Sell” rating from available analysts and a recent DOJ investigation into trading of its shares disclosed in October 2025. The investigation led to an 18.56 % drop in the stock price in November 2025, reflecting concerns about potential legal liabilities and reputational risk. The ATM program is viewed as a proactive measure to mitigate these risks by ensuring sufficient capital for operations and potential future financing needs.
While the ATM offering does not alter Regencell’s long‑term strategic focus on developing natural therapies for neurological disorders, it signals management’s recognition of the company’s current cash constraints and the need for a flexible financing tool. The program’s ability to tap the market when conditions are favorable positions Regencell to maintain momentum in its research pipeline without the immediate pressure of a large, one‑time equity issuance.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.